CN108653319A - Application of the ozone carburetion in gynaecological inflammation disease - Google Patents
Application of the ozone carburetion in gynaecological inflammation disease Download PDFInfo
- Publication number
- CN108653319A CN108653319A CN201710215179.6A CN201710215179A CN108653319A CN 108653319 A CN108653319 A CN 108653319A CN 201710215179 A CN201710215179 A CN 201710215179A CN 108653319 A CN108653319 A CN 108653319A
- Authority
- CN
- China
- Prior art keywords
- oil
- ozone
- fatty acid
- injection
- unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to application of the ozone carburetion in gynaecological inflammation disease, mammitis, mastitis, vulvitis, vaginitis, cervicitis, endometritis, condyloma acuminatum, pelvic infecton can effectively be prevented and treated by being given by way of the described oral, intraperitoneal injection, bowel lavage, gavage, intravenous injection, hypodermic injection, intramuscular injection, external application, drops and suppository.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to ozone carburetion for gynaecological inflammation disease treatment and with treatment
The combination therapies of gynaecological inflammation disease.
Background technology
Velio Bocci exist《Ozone therapy》Many can be played using the ozone gas of low dosage by being outlined in one book
Beneficial functions, and without side-effects, i.e. ozone therapy（See what Velio Bocci write《Oxygen-Ozone Therapy》, Beijing
University Hospital publishing house, 2004）.Ozone therapy can be realized by a variety of administration routes, and be generated not for various disease
Same effect.The external application of ozone carburetion is as antiseptic, deodorant for treating for skin disease drugs such as bedsore and ulcer.Therefore,
Know that ozone has oxidation and antibacterial action.By the direct gavage of ozone carburetion controlling for the microbial gastritis of H. pylori
It treats.Ozone gas is subcutaneously injected to treat slow virus hepatitis and vascular conditions in muscle.Vagina is passed directly into ozone gas
Inflammation and bacterium infection can be cured.Ozone gas is directly mixed with the blood of certain volume in vitro, then is fed back to patient
It is referred to as self hemotherapy, human internal environment can be improved, reduces the sensibility and enhancing immunity of organisms of body.Rectum is direct
Blowing ozone's gas can improve the symptom of Parkinson's disease（See Lamberto Re, Mohamed N. Mawsouf, Silvia
Menendez, Olga S. Leon, Gregorio M. Sanchez, and Frank Hernandez write《Ozone
Therapy: Clinical and Basic Evidence of Its Therapeutic Potential》, Archives
Of Medical Research, 2008,39: 17-26）.Abdominal cavity to ozone gas can cardioprotection from Acute myocardial obstruct
The damage of plug（Clara Di Filippo, Margherita Luongo, Raffaele Marfella, Franca
Ferraraccio, Biagio Lettieri, Annalisa Capuano, Francesco Rossi, Michele D'
What Amico write《Oxygen/ozone protects the heart from acute myocardial infarction
through local increase of eNOS activity and endothelial progenitor cells
recruitment》, Naunyn-Schmied Arch Pharmacol, 2010,382:287–291）.Structurally, although
Ozone carburetion and ozone gas（:O-O-O）It is not same substance, but ozone carburetion is obtained by the addition ozone to oil,
Therefore there is ozonide structure in the molecule thereof, it is similar to the function of ozone gas.Any of the above administration route shows ozone
Directly it can be absorbed by organisms and function in a manner of gas.The function of ozone gas may by following three approach come
It realizes：（1）, ozone pass through biochemical reaction in vivo, generate the substance of similar active oxygen（Hydroxyl radical free radical OH-, super oxygen it is cloudy
Ion O2 -Deng）, body oxidation-reduction system is affected extensively；（2）, ozone can cause endothelial progenitor cells assemble and promote an oxygen
Change nitrogen（NO）Generation, play the role of vasodilatory；（3）, ozone can inducing bone marrow stem cell to vascular injury site, promote
It is rebuild into damage vascular repair, but specific mechanism is still not clear.
There are many defects for above-mentioned administration route：It is contacted on the way with too many substance, it is difficult to ensure that gas enters having for body
Imitate concentration.If giving the excessive body that easily induces generates uncomfortable reaction, and operating process is cumbersome, along with the course for the treatment of is longer, patient
It is difficult to receive.Especially self hemotherapy, 2~3 times weekly, continuous 10 weeks as a treatment course.The present invention is with oil and ozone addition
Mode obtains ozone carburetion, then this oil is wrapped up with capsulae enterosolubilis, can overcome the shortcomings for directly using ozone gas.
Both ensured that ozone carburetion was not contacted with extraneous any substance, can also preserve steadily in the long term under normal conditions；Control ozone can also be quantified
Carburetion enters body, to avoid passing through other administering mode administrations, artificially causes dose improper.Ozone carburetion capsulae enterosolubilis
Administration route is directly oral, and minimum is injured to body, and operation is simple, is convenient for carrying, and has been established for its popularization good
Basis.
In ozonizing oil product, ozonisation olive oil, sunflower oil, soybean oil are used for ulcer as antiseptic, deodorant
The topical drug of equal treating for skin disease has listed.But by ozone carburetion be made the form of capsulae enterosolubilis pass through it is directly oral
Mode enters body and generates effect, there is no report at present.In the present invention, by directly taking orally ozone carburetion capsulae enterosolubilis,
Intraperitoneal injection, bowel lavage, gavage, intravenous injection, hypodermic injection, intramuscular injection, external application, drops and suppository mode, can generate
Drug effect.
Invention content
The purpose of the present invention is preventing and treating various wounds and inflammation using ozonisation oil formulation and administration route, make
It is standby easy, of low cost.It verifies by clinic application, the present invention has significant in efficacy, has no toxic side effect, the advantages that high efficiency.
In the present invention, why select one kind in the various oil described in claim 1,2, two kinds and two or more,
It is because these oily unsaturated fatty acid contents are higher, the unsaturated fatty acid of wherein walnut oil is up to 92% or more, in unsaturation
At least one olefinic double bond in fatty acid structure.If by claim 1,2 one kind, two kinds and it is two or more contain insatiable hunger
High oil is mixed with one kind in claim 3~7, two kinds and two or more surfactants with aliphatic acid, also can with it is smelly
Addition reaction occurs for oxygen.As long as it can be seen that in the structure of addition product there are alkene unsaturated bond can with ozone occur addition reaction,
Unsaturated bond number is more, and reaction is more easy to happen, and more with the amount of ozone addition, and addition product can carry ozone molecule
Number is also more.
In order to achieve the above objectives, the technical solution adopted by the present invention will combine following production process and embodiment to carry out
Simple illustration.
1, ozone gas is prepared.
2, ozone carburetion is prepared.
3, ozonisation olive oil capsulae enterosolubilis is prepared.
4, the ozone carburetion capsulae enterosolubilis containing surfactant is prepared.
5, the ozone carburetion capsulae enterosolubilis containing cosurfactant and surfactant is prepared.
6, ozonize olive oil capsule and ozonisation olive oil to mammitis, mastitis, vulvitis, vaginitis, cervicitis,
The Experiment on therapy of endometritis, condyloma acuminatum, pelvic infecton.
Specific implementation mode
It elaborates with reference to embodiments to the specific implementation mode of the present invention.
Embodiment 1 ozonizes olive oil and prepares
1, ozone gas is prepared.The present invention prepares ozone gas using medical oxygen by ozone generator.
DRO3-A type ozone machines selected from Xi'an Derun Bio-Technology Co., Ltd.'s design production（Gong Shuai≤55W）.
2, it prepares ozone carburetion and ozone carburetion capsulae enterosolubilis whole process need be carried out at 20~25 DEG C, it is ensured that ozonisation
Pyrolytic reaction will not occur for oil.
3, olive oil 3kg is placed in reaction kettle；Ozone is with 150m3/ h flow velocitys are added, and total reaction time is 20 hours.Reaction
After, residual air inactivation.
4, a concentration of 40 mg/L of ozonisation olive oil is obtained, 25 DEG C can stablize preservation ten months.
Embodiment 2 ozonizes olive oil capsulae enterosolubilis and prepares
Prepare ozonisation olive oil capsulae enterosolubilis.
（1）, capsule material preparation:By weight 3：3：1：1 ratio weighs water, gelatin, glycerine and glutinous rice flour or starch falls
Enter in glue tank, temperature is first arranged to 75 DEG C when colloidal sol, starts when temperature reaches 60 DEG C plus water, adds water 10 minutes, uses hand
Touching has micro- boiling hot feeling, is initially added into glycerine, stirs 2 minutes, takes 2 times, refunded in glue tank from glue pot bottom, adds gelatin rapidly,
Mixing time is 2 hours, and temperature is set as 60 DEG C after stirring, stands de-bubbled 8 hours.
（2）, using pressing prepare ozonisation olive oil capsulae enterosolubilis, capacity 0.25mL.
22 DEG C of glue capsules of room temperature, rubber thickness are 0.7mm, and capacity 0.25mL, soft capsule obtained is cooling 8 in rotating cage
Hour, it comes out of steamer, is drying to obtain ozonisation olive oil capsulae enterosolubilis, it is spare that refrigeration is protected from light in 4 DEG C.
It is prepared by the capsulae enterosolubilis that embodiment 3 ozonizes olive oil, soybean oil and peanut oil miscella
1, ozone gas is prepared.The present invention prepares ozone gas using medical oxygen by ozone generator.
DRO3-A type ozone machines selected from Xi'an Derun Bio-Technology Co., Ltd.'s design production（Gong Shuai≤55W）.
2, it prepares ozone carburetion and ozone carburetion capsulae enterosolubilis whole process need be carried out at 20~25 DEG C, it is ensured that ozonisation
Pyrolytic reaction will not occur for oil.
3, in olive oil 1kg, soybean oil 1kg and peanut oil 1kg merging reaction kettles；Ozone is with 150m3/ h flow velocitys are added, always
Reaction time is 20 hours.After reaction, residual air inactivates.
4, it is 40mg/L to obtain ozonisation miscella concentration, and 25 DEG C can stablize preservation ten months.
5, ozonisation miscella capsulae enterosolubilis is prepared.
（1）, capsule material preparation:By weight 3：3：1：1 ratio weighs water, gelatin, glycerine and glutinous rice flour or starch falls
Enter in glue tank, temperature is first arranged to 75 DEG C when colloidal sol, starts when temperature reaches 60 DEG C plus water, adds water 10 minutes, uses hand
Touching has micro- boiling hot feeling, is initially added into glycerine, stirs 2 minutes, takes 2 times, refunded in glue tank from glue pot bottom, adds gelatin rapidly,
Mixing time is 2 hours, and temperature is set as 60 DEG C after stirring, stands de-bubbled 8 hours.
（2）, using pressing prepare ozonisation miscella capsulae enterosolubilis, capacity 0.25mL.
22 DEG C of glue capsules of room temperature, rubber thickness are 0.7mm, and capacity 0.25mL, soft capsule obtained is cooling 8 in rotating cage
Hour, it comes out of steamer, is drying to obtain ozonisation miscella capsulae enterosolubilis, it is spare that refrigeration is protected from light in 4 DEG C.
It is prepared by ozonisation olive oil capsulae enterosolubilis of the embodiment 4 containing surfactant
1, ozone gas is prepared.The present invention prepares ozone gas using medical oxygen by ozone generator.
DRO3-A type ozone machines selected from Xi'an Derun Bio-Technology Co., Ltd.'s design production（Gong Shuai≤55W）.
2, it prepares ozone carburetion and ozone carburetion capsulae enterosolubilis whole process need be carried out at 20~25 DEG C, it is ensured that ozonisation
Pyrolytic reaction will not occur for oil.
3, olive oil 3kg is placed in reaction kettle, is slowly added to sorbitan monooleate polyoxyethylene ether（Tween 80）
20mL, mixing, ozone is with 150m3/ h flow velocitys are added, and total reaction time is 20 hours.After reaction, residual air inactivates.
4, a concentration of 40 mg/L of ozonisation olive oil is obtained, 25 DEG C can stablize preservation ten months.
5, the ozonisation olive oil capsulae enterosolubilis containing surfactant is prepared.
（1）, capsule material preparation:By weight 3：3：1：1 ratio weighs water, gelatin, glycerine and glutinous rice flour or starch falls
Enter in glue tank, temperature is first arranged to 75 DEG C when colloidal sol, starts when temperature reaches 60 DEG C plus water, adds water 10 minutes, uses hand
Touching has micro- boiling hot feeling, is initially added into glycerine, stirs 2 minutes, takes 2 times, refunded in glue tank from glue pot bottom, adds gelatin rapidly,
Mixing time is 2 hours, and temperature is set as 60 DEG C after stirring, stands de-bubbled 8 hours.
（2）, using pressing prepare ozonisation olive oil capsulae enterosolubilis, capacity 0.25mL.
22 DEG C of glue capsules of room temperature, rubber thickness are 0.7mm, and capacity 0.25mL, soft capsule obtained is cooling 8 in rotating cage
Hour, it comes out of steamer, is drying to obtain the ozonisation olive oil capsulae enterosolubilis containing surfactant, it is spare that refrigeration is protected from light in 4 DEG C.
Embodiment 5 is prepared containing the ozonisation olive oil capsulae enterosolubilis of surfactant and cosurfactant
1, ozone gas is prepared.The present invention prepares ozone gas using medical oxygen by ozone generator.
DRO3-A type ozone machines selected from Xi'an Derun Bio-Technology Co., Ltd.'s design production（Gong Shuai≤55W）.
2, it prepares ozone carburetion and ozone carburetion capsulae enterosolubilis whole process need be carried out at 20~25 DEG C, it is ensured that ozonisation
Pyrolytic reaction will not occur for oil.
3, olive oil 3kg is placed in reaction kettle, is slowly added to sorbitan monooleate polyoxyethylene ether（Tween 80）
20mL and straight alcohol 20mL, mixing, ozone is with 150m3/ h flow velocitys are added, and total reaction time is 20 hours.After reaction, remaining
Gas inactivates.
4, a concentration of 40 mg/L of ozonisation olive oil is obtained, 25 DEG C can stablize preservation ten months.
5, the ozonisation olive oil capsulae enterosolubilis containing surfactant and cosurfactant is prepared.
（1）, capsule material preparation:By weight 3：3：1：1 ratio weighs water, gelatin, glycerine and glutinous rice flour or starch falls
Enter in glue tank, temperature is first arranged to 75 DEG C when colloidal sol, starts when temperature reaches 60 DEG C plus water, adds water 10 minutes, uses hand
Touching has micro- boiling hot feeling, is initially added into glycerine, stirs 2 minutes, takes 2 times, refunded in glue tank from glue pot bottom, adds gelatin rapidly,
Mixing time is 2 hours, and temperature is set as 60 DEG C after stirring, stands de-bubbled 8 hours.
（2）, using pressing prepare ozonisation olive oil capsulae enterosolubilis, capacity 0.25mL.
22 DEG C of glue capsules of room temperature, rubber thickness are 0.7mm, and capacity 0.25mL, soft capsule obtained is cooling 8 in rotating cage
Hour, it comes out of steamer, is drying to obtain the ozonisation olive oil capsulae enterosolubilis containing surfactant and cosurfactant, is protected from light in 4 DEG C
It refrigerates spare.
The clinical test of 6 present invention ozonisation olive oil treatment gynaecological inflammation disease of embodiment
Specific experiment process is as follows:
The clinical observation on the therapeutic effect of drug of the present invention
1. clinical case：
In the gynaecological inflammation disease patient 320 of the demonstration areas Yang Ling hospital diagnosis, disease type since selecting 2010 ~ 2016
Including mammitis, mastitis, vulvitis, vaginitis, cervicitis, endometritis, condyloma acuminatum, pelvic infecton etc..It is above-mentioned each
Sick 40 cases, including it is bacillary（Aerobic bacteria, anaerobic bacteria）, mycotic, trichomonas, fungoid, Chlamydia (and/or gonococcus), branch
Various inflammation caused by substance, patient are randomly divided into two groups for the treatment of group and control group, treatment group 20, control group 20, and in total 8
Kind disease.The age of two groups of cases for the treatment of group and control group, gender, illness rank random distribution, no significant difference have comparable
Property, two groups are kept on a diet as required.
2. therapy：Treatment group patient uses ozonisation olive oil and its capsule prepared by the embodiment of the present invention 1 and 2
For preparation, take orally on an empty stomach one a time, 1 times a day, 90 days as a treatment course.External application ozonisation olive oil is applied to affected part, or
It drips into vagina or uterus 2ml once a day, 3 days as one therapeutic course；Control group selection routine clinical treatment drug or method, 3 days
It is as a treatment course, if effectively, then carry out a course for the treatment of.
3. therapeutic effect evaluation criteria
(1) it cures：Ulcer, underbelly shouting pain, itch, leukorrhea, frequent micturition are with urgent urination and odynuria, heating paresthesia recovery from illness；Without purulent secretion
Object is discharged, and ulcer surface, peculiar smell disappear；Without inflammatory cell infiltration phenomenon.
(2) it improves：Above-mentioned symptom is alleviated.
(3) invalid：Clinical symptoms are unchanged.
4. treatment results：
1 mammitis treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 15 | 5 | 0 | 100 | 0 |
| Control group | 20 | 13 | 3 | 4 | 80 | 5 |
2 mastitis treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 19 | 1 | 0 | 100 | 0 |
| Control group | 20 | 12 | 4 | 4 | 80 | 2 |
3 vulvitis treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 19 | 1 | 0 | 100 | 0 |
| Control group | 20 | 10 | 5 | 5 | 75 | 3 |
4 vaginitis treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 20 | 0 | 0 | 100 | 0 |
| Control group | 20 | 6 | 7 | 7 | 65 | 4 |
5 cervicitis treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 20 | 0 | 0 | 100 | 0 |
| Control group | 20 | 7 | 7 | 6 | 70 | 2 |
6 endometritis treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 18 | 2 | 0 | 100 | 0 |
| Control group | 20 | 3 | 6 | 11 | 45 | 0 |
7 treatment of condyloma acuminatum group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 19 | 1 | 0 | 100 | 0 |
| Control group | 20 | 5 | 7 | 8 | 60 | 0 |
8 pelvic infecton treatment group of table and control group curative effect compare
| Group | Number of cases | Recovery from illness/example | Improvement/example | In vain/example | Effective percentage/% | Recurrence |
| Treatment group | 20 | 20 | 0 | 0 | 100 | 0 |
| Control group | 20 | 9 | 3 | 8 | 60 | 0 |
The above results show that treatment group's recovery from illness ratio is noticeably greater than control group, illustrate that ozonizing olive oil cures gynaecological imflammation disease
Sick significant effect, to mammitis, mastitis, vulvitis, vaginitis, cervicitis, endometritis, condyloma acuminatum, pelvic infecton etc.
With healing and therapeutic effect.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended power
Profit requires rather than above description limits, it is intended that all by what is fallen within the meaning and scope of the equivalent requirements of the claims
Variation is included within the present invention.
The above described is only a preferred embodiment of the present invention, being not that the invention has other forms of limitations, appoint
What those skilled in the art changed or be modified as possibly also with the technology contents of the disclosure above equivalent variations etc.
Imitate embodiment.But it is every without departing from technical solution of the present invention content, according to the technical essence of the invention to above example into
Row modification or equivalent replacement of some of the technical features.All within the spirits and principles of the present invention, appoint made by
What modification, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (9)
1. a kind of new application of ozone carburetion, which is characterized in that oil is at least selected from olive oil, soya-bean oil, sunflower oil, linseed
Oil, rapeseed oil, Semen setariae oil, corn oil, maize germ oil, sesame oil, cottonseed oil, castor oil, peanut oil, tea-seed oil, perilla herb oil,
One in safflower seed oil, apricot kernel oil, hazelnut oil, walnut oil, pine-seed oil, shinyleaf yellowhorn oil, edible blend oil, cod-liver oil and fish oil
Kind, by the electrophilic addition ozone to oil, the glutinous rice or starch material that capacity is 0.1~0.75mL is made in obtained ozone carburetion
Capsulae enterosolubilis is contained with 2~100mL vials, with the dosage of 0.1 ~ 100mL, is administered and is noted using abdominal cavity by oral route
Penetrate, bowel lavage, gavage, intravenous injection, hypodermic injection, intramuscular injection, external application, drops and suppository mode give, can be used in making
The drug of standby prevention and treatment gynaecological inflammation disease, it includes mammitis, mastitis, vulvitis, vagina that gynaecological inflammation disease, which is selected from,
Any type in inflammation, cervicitis, endometritis, condyloma acuminatum, pelvic infecton.
2. oil according to claim 1, which is characterized in that carry out mixing and two two-by-two to oil described in claim 1
Mixing of the kind to oil, by electrophilic addition ozone, glutinous rice or shallow lake that capacity is 0.1~0.75mL is made in obtained ozone carburetion
Powder material capsulae enterosolubilis is contained with 2~100mL vials, with the dosage of 0.1 ~ 100mL, is administered and uses by oral route abdomen
Chamber injection, bowel lavage, gavage, intravenous injection, hypodermic injection, intramuscular injection, external application, drops and suppository mode give, Neng Gouyong
In prepare prevention and treatment gynaecological inflammation disease drug, gynaecological inflammation disease be selected from include mammitis, mastitis, vulvitis,
Any type in vaginitis, cervicitis, endometritis, condyloma acuminatum, pelvic infecton.
3. any one oil according to claims 1 to 2, which is characterized in that by selecting nonionic surfactant, the moon
One kind, two kinds and two or more mixing in ionic surface active agent and cationic surfactant, with claim 1~2
Any one of described oil mixes, and by electrophilic addition ozone, obtains the ozone carburetion containing surfactant and capacity is made
It is contained for the glutinous rice or starch material capsulae enterosolubilis of 0.1~0.75mL, with 2~100mL vials, with the agent of 0.1 ~ 100mL
Amount is administered and by oral route using intraperitoneal injection, bowel lavage, gavage, intravenous injection, hypodermic injection, intramuscular injection, external application, drop
The mode of agent and suppository is given, and the drug for preparing prevention and treatment gynaecological inflammation disease is can be used in, and gynaecological inflammation disease is selected from
Including any type in mammitis, mastitis, vulvitis, vaginitis, cervicitis, endometritis, condyloma acuminatum, pelvic infecton.
4. surfactant according to claim 3, which is characterized in that selected from glycerine unsaturated fatty acid ester, polyglycereol
Unsaturated fatty acid ester, propylene glycol unsaturated fatty acid ester, sorbitan unsaturated fatty acid ester, polyoxyethylene sorbitol
Acid anhydride unsaturated fatty acid ester, polyoxyethylene unsaturated fatty acid ester, mannitol unsaturated fatty acid ester, pentaerythrite are unsaturated
It is non-in aliphatic ester, sucrose unsaturated fatty acid ester, polyethylene glycol unsaturated alkyl ether and polypropylene glycol unsaturated alkyl ether
One kind in ionic surface active agent, two kinds and two or more.
5. surfactant according to claim 3, which is characterized in that selected from unsaturated fatty acid salt, unsaturated fat
Alcohol sulfuric ester salt, alpha-sulfo unsaturated fatty acid ester, olefin sulphates and the anion surfactant in alkene sulfonate
It is a kind of, two kinds and two or more.
6. surfactant according to claim 3, which is characterized in that be selected from the monosubstituted trimethyl of unsaturated aliphatic hydrocarbyl moiety
Ammonium salt, two substituted dimethyl ammonium salt of unsaturated aliphatic hydrocarbyl moiety, the monosubstituted dimethyl benzyl ammonium salt of unsaturated aliphatic hydrocarbyl moiety, unsaturation
The monosubstituted amine acylate of aliphatic group, unsaturated aliphatic hydrocarbyl moiety two replace amine acylate and N- methyl diethanolamine insatiable hungers
With one kind of the cationic surfactant in aliphatic ester hydrochloride, two kinds and two or more.
7. any one surfactant according to claim 3, which is characterized in that selected from food-grade petroleum ether, poly- second
Glycol unsaturated alkyl ether, one kind of sorbitan monoesters polyoxyethylene ether surface active agent and two kinds.
8. any one according to claims 1 to 7 oil, which is characterized in that selection and ethyl alcohol, propylene glycol, glycerine, oneself
One kind, two kinds and two or more mixing in glycol, butanediol, pentanediol, butantriol, hexanetriol, pass through electrophilic addition ozone
The ozone carburetion containing cosurfactant and surfactant is obtained, glutinous rice or starch material that capacity is 0.1~0.75mL is made
Matter capsulae enterosolubilis is contained with 2~100mL vials, with the dosage of 0.1 ~ 100mL, is administered and is noted using abdominal cavity by oral route
Penetrate, bowel lavage, gavage, intravenous injection, hypodermic injection, intramuscular injection, external application, drops and suppository mode give, can be used in making
The drug of standby prevention and treatment gynaecological inflammation disease, it includes mammitis, mastitis, vulvitis, vagina that gynaecological inflammation disease, which is selected from,
Any type in inflammation, cervicitis, endometritis, condyloma acuminatum, pelvic infecton.
9. ozone carburetion and its any one administration route made of any one according to claims 1 to 8, feature
It is, which can be selected from packet by the approach with the drug for the treatment of gynaecological inflammation disease, gynaecological inflammation disease
Include any type disease in mammitis, mastitis, vulvitis, vaginitis, cervicitis, endometritis, condyloma acuminatum, pelvic infecton
Drug combination can effectively prevent and treat above-mentioned disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710215179.6A CN108653319A (en) | 2017-04-02 | 2017-04-02 | Application of the ozone carburetion in gynaecological inflammation disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710215179.6A CN108653319A (en) | 2017-04-02 | 2017-04-02 | Application of the ozone carburetion in gynaecological inflammation disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108653319A true CN108653319A (en) | 2018-10-16 |
Family
ID=63784839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710215179.6A Pending CN108653319A (en) | 2017-04-02 | 2017-04-02 | Application of the ozone carburetion in gynaecological inflammation disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108653319A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302302A (en) * | 2019-08-06 | 2019-10-08 | 阿谷巴科技（唐山）有限公司 | A kind of antibacterial liquid formulations |
| CN110812378A (en) * | 2019-11-25 | 2020-02-21 | 湖南易兴建筑有限公司 | Quaternary ammonium salt ozone oil and preparation method thereof |
| CN111012793A (en) * | 2019-12-30 | 2020-04-17 | 深圳仟枝生物科技股份有限公司 | Antibacterial and detoxicating gynecological gel and preparation method thereof |
| CN112773814A (en) * | 2019-11-05 | 2021-05-11 | 深圳市安易达生物科技有限公司 | Application of ozone oil in preparing medicine for enema treatment |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178632A (en) * | 2011-05-06 | 2011-09-14 | 石平安 | Application of ozonized oil to preparation of raw materials of medical health-care products |
| CN105920075A (en) * | 2016-06-02 | 2016-09-07 | 陈泽鑫 | Externally-used drug of ozone antibacterial agent |
| CN106309474A (en) * | 2016-11-01 | 2017-01-11 | 侯建生 | Application of ozonized oil in hyperplasia diseases and infertility |
| CN106344606A (en) * | 2016-11-01 | 2017-01-25 | 侯建生 | Medical applications and administration route for ozonized oil |
-
2017
- 2017-04-02 CN CN201710215179.6A patent/CN108653319A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178632A (en) * | 2011-05-06 | 2011-09-14 | 石平安 | Application of ozonized oil to preparation of raw materials of medical health-care products |
| CN105920075A (en) * | 2016-06-02 | 2016-09-07 | 陈泽鑫 | Externally-used drug of ozone antibacterial agent |
| CN106309474A (en) * | 2016-11-01 | 2017-01-11 | 侯建生 | Application of ozonized oil in hyperplasia diseases and infertility |
| CN106344606A (en) * | 2016-11-01 | 2017-01-25 | 侯建生 | Medical applications and administration route for ozonized oil |
Non-Patent Citations (2)
| Title |
|---|
| ZKHJYX: ""医用臭氧在临床实践的应用"", 《HTTPS://WWW.19LOU.COM/BOARD-123456802951210-THREAD-178501362742456211-1.HTML》 * |
| 宋敏: ""浅谈臭氧在临床中的应用"", 《中国实用医药》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302302A (en) * | 2019-08-06 | 2019-10-08 | 阿谷巴科技（唐山）有限公司 | A kind of antibacterial liquid formulations |
| CN112773814A (en) * | 2019-11-05 | 2021-05-11 | 深圳市安易达生物科技有限公司 | Application of ozone oil in preparing medicine for enema treatment |
| CN110812378A (en) * | 2019-11-25 | 2020-02-21 | 湖南易兴建筑有限公司 | Quaternary ammonium salt ozone oil and preparation method thereof |
| CN111012793A (en) * | 2019-12-30 | 2020-04-17 | 深圳仟枝生物科技股份有限公司 | Antibacterial and detoxicating gynecological gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108653319A (en) | Application of the ozone carburetion in gynaecological inflammation disease | |
| CN108653320A (en) | The medical usage of ozone carburetion promotion wound, inflammation healing | |
| CN109078165A (en) | A kind of composition and the preparation method and application thereof for the nursing of women privates | |
| CN106309474A (en) | Application of ozonized oil in hyperplasia diseases and infertility | |
| CN102028705A (en) | Gynecologic article containing biological antifungal components | |
| CN102743739B (en) | Preparation method for blattodea polypeptide substance, and medical use of blattodea polypeptide substance in anti-herpesvirus | |
| CN106466327A (en) | Application in dermatosis, obesity and phlebothrombosises preventing and treating for the ozone carburetion | |
| CN102274174A (en) | Oil suspension agent of benzimidazole medicine | |
| CN107184911A (en) | One kind is used to prevent cervical carcinoma and treatment papillomavirus（HPV）Infection and the product and preparation method of colpitis | |
| CN103830385B (en) | Psoriasis paster | |
| CN104173871A (en) | Traditional Chinese medicine composition for treating vulvitis and applications of traditional Chinese medicine composition | |
| CN106860474A (en) | A kind of new application of ozone carburetion | |
| JP2009269904A (en) | Herbal medicinal composition for curing external wound and bedsore and method of manufacturing medicine from the composition | |
| CN108685941A (en) | Application of the ozone carburetion in disease of digestive tract and inflammation | |
| CN108653318A (en) | Application of the ozone carburetion in eye and ear disease | |
| ES2555662T3 (en) | Egg preparation with regenerative, analgesic and / or anti-inflammatory properties | |
| CN107281536A (en) | A kind of wick for being used for sanitary napkin and protection pad and preparation method thereof | |
| CN103800401B (en) | Granulation promoting healing ointment | |
| CN106389463A (en) | Application of ozonized oil in prevention and treatment of autoimmune disease and irritable bowel syndrome | |
| CN100348209C (en) | Natural lycopene compound oil preparation and capsule and its preparing method and use | |
| CN108685940A (en) | Application of the ozone carburetion in infectious diseases | |
| CN107569453A (en) | It is a kind of that there are the anti-ageing little Huang breasts preparation method and application for repairing jelly scald and eczema containing egg oil | |
| CN107184605A (en) | A kind of medicine for treating spinal cord injury and its application | |
| CN103751277A (en) | Infantile traditional Chinese medicine cooling patch | |
| CN106491635A (en) | Ozone carburetion and the drug combination for treating hypertension agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |